Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors

• Published in: EMBO reports Vol. 26; no. 2; pp. 521 - 559
• Main Authors: Shi, Yuhao, McKenery, Amber, Dolan, Melissa, Mastri, Michalis, Hill, James W, Dommer, Adam, Benzekry, Sebastien, Long, Mark, Abrams, Scott I, Puzanov, Igor, Ebos, John M L
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 27.01.2025; EMBO Press
• Subjects: Animals; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - genetics; B7-H1 Antigen - metabolism; Biomedical and Life Sciences; Cancer; Cell Line, Tumor; Drug Resistance, Neoplasm; EMBO03; EMBO19; EMBO37; Humans; Immune Checkpoint Inhibitors - pharmacology; Interferon Type I - metabolism; Life Sciences; Mice; Neoplasms - drug therapy; Neoplasms - immunology; Neoplasms - metabolism; Neoplasms - pathology; Signal Transduction - drug effects; Resistance; IFN; PD-L1; Immune-checkpoint; Secretome

Therapeutic inhibition of programmed cell death ligand (PD-L1) is linked to alterations in interferon (IFN) signaling. Since IFN-regulated intracellular signaling can control extracellular secretory programs in tumors to modulate immunity, we examined IFN-related secretory changes in tumor cells fol...